Compare SLNH & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNH | MOLN |
|---|---|---|
| Founded | 1961 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.8M | 164.2M |
| IPO Year | N/A | 2021 |
| Metric | SLNH | MOLN |
|---|---|---|
| Price | $1.30 | $4.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $5.00 | $3.75 |
| AVG Volume (30 Days) | ★ 5.2M | 4.3K |
| Earning Date | 11-17-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,782,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $45.98 | $999.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $3.36 |
| 52 Week High | $5.14 | $5.91 |
| Indicator | SLNH | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 38.93 | 54.75 |
| Support Level | $1.25 | $4.16 |
| Resistance Level | $1.65 | $4.44 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 4.81 | 75.00 |
Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.